Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Terminated 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Other solid neoplasm 1Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma, Large B-Cell, Diffuse 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Lobular 1

Interventions

pembrolizumab 524Specimen Handling 383Carboplatin 377Magnetic Resonance Spectroscopy 336Cisplatin 332Nivolumab 308Cyclophosphamide 298Radiotherapy 257Paclitaxel 255Gemcitabine 235Biopsy 235Bevacizumab 218Dexamethasone 169durvalumab 168Oxaliplatin 163Capecitabine 158Rituximab 157Fluorouracil 149venetoclax 147Docetaxel 147Etoposide 142Drug Therapy 142atezolizumab 141Doxorubicin 134Ipilimumab 129Radiosurgery 120Prednisone 120Lenalidomide 119Leucovorin 113fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Drugs, Generic × 1 year × Clear all
NCT07085728 2026-05-15

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
74 enrolled
Plasma cell

Multiple Myeloma

NCT05179603 2025-12-24

A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

Sanofi

Phase 2 Terminated
14 enrolled 15 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03620643 2025-10-30

ROLo

Royal Marsden NHS Foundation Trust

Phase 2 Completed
33 enrolled 13 charts
BreastGastrointestinal

Stomach Neoplasms, Carcinoma, Lobular, Triple Negative Breast Neoplasms

NCT04914897 2025-10-02

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

Sanofi

Phase 2 Terminated
106 enrolled 21 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡